Approximately 85–90% of GISTs harboring KIT or PDGFRA mutations benefit from imatinib treatment before or after surgery and in the setting of unresectable/metastatic disease (12, 13), except specific mutation such as PDGFRA exon 18 D842V (14). Here, PDGFRA is linked to metastatic neoplasm.